Beta Bionics (NASDAQ:BBNX) Releases Earnings Results, Misses Estimates By $1.40 EPS

Beta Bionics (NASDAQ:BBNX) released its quarterly earnings data on Tuesday. The company reported ($1.82) earnings per share for the quarter, missing the consensus estimate of ($0.42) by ($1.40), Zacks reports. The firm had revenue of $20.44 million during the quarter, compared to analyst estimates of $20.01 million. Beta Bionics updated its FY 2025 guidance to EPS.

Beta Bionics Stock Down 13.6 %

NASDAQ BBNX opened at $13.15 on Thursday. Beta Bionics has a 12 month low of $12.14 and a 12 month high of $24.50.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on BBNX shares. Robert W. Baird assumed coverage on shares of Beta Bionics in a research report on Thursday, February 20th. They set a “neutral” rating and a $20.00 price target on the stock. LADENBURG THALM/SH SH started coverage on shares of Beta Bionics in a research report on Thursday, February 20th. They set a “neutral” rating and a $20.00 price target for the company. Leerink Partners initiated coverage on Beta Bionics in a report on Monday, February 24th. They issued an “outperform” rating and a $28.00 price target for the company. Leerink Partnrs upgraded Beta Bionics to a “strong-buy” rating in a research note on Monday, February 24th. Finally, Stifel Nicolaus started coverage on Beta Bionics in a research note on Monday, February 24th. They issued a “buy” rating and a $25.00 target price for the company. Three equities research analysts have rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, Beta Bionics presently has an average rating of “Moderate Buy” and a consensus target price of $24.83.

Insider Transactions at Beta Bionics

In other news, insider Mike Mensinger purchased 33,350 shares of the stock in a transaction dated Friday, January 31st. The stock was acquired at an average cost of $17.00 per share, for a total transaction of $566,950.00. Following the acquisition, the insider now owns 59,019 shares of the company’s stock, valued at $1,003,323. The trade was a 129.92 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this link. Also, major shareholder Hadley Harbor Aggre Wellington acquired 1,000,000 shares of Beta Bionics stock in a transaction that occurred on Friday, January 31st. The shares were purchased at an average price of $17.00 per share, for a total transaction of $17,000,000.00. Following the completion of the purchase, the insider now directly owns 3,901,599 shares of the company’s stock, valued at $66,327,183. The trade was a 34.46 % increase in their ownership of the stock. The disclosure for this purchase can be found here.

Beta Bionics Company Profile

Beta Bionics, Inc is a commercial-stage medical device company. It engages in the design, development, and commercialization of solutions for insulin-requiring people with diabetes. The company was founded by Edward R. Damiano on October 21, 2015 and is headquartered in Irvine, CA.